A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Bristol-Myers Squibb
Protocol Number
Bristol-Myers Squibb CA209-602
Cancer Diagnosis
To Learn More Call
201-510-0910